BRAFi/MEKi combination therapy is a first-line option in patients with BRAF-mutant metastatic melanoma (National Comprehensive Cancer Network Guidelines Version 1.2017, www.nccn.org). This evidence concerns the gene BRAF and metastatic melanoma.